Ventricular septal rupture following abciximab infusion.
Ventricular septal rupture is a rare complication of myocardial infarction. Despite a significant reduction in its incidence with reperfusion therapy, thrombolysis has been implicated in the pathogenesis of septal rupture. There is little information regarding the impact of glycoprotein IIb-IIIa receptor blockers on ventricular septal rupture. We report a case of rupture of the ventricular septum occurring after treatment with the glycoprotein IIb-IIIa receptor blocker abciximab, in the absence of thrombolysis.
Arnold
Jayanth R
JR
Department of Cardiology, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK. ranjitarnold@yahoo.co.uk
Timperley
Jonathan
J
Mitchell
Andrew R J
AR
Westaby
Stephen
S
Ormerod
Oliver
O
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D000925:Anticoagulants / Q000008:administration & dosage*; D002304:Cardiac Pacing, Artificial; D002315:Cardiopulmonary Bypass; D017023:Coronary Angiography; D054855:Drug-Eluting Stents; D004452:Echocardiography; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000009:adverse effects*; D007262:Infusions, Intravenous / Q000009:adverse effects*; D007423:Intra-Aortic Balloon Pumping; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy; D012422:Rupture, Spontaneous; D018658:Ventricular Septal Rupture / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab